NDAORALTABLET
Approved
Oct 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Tolazamide is an oral sulfonylurea antidiabetic agent approved in 1984 for the management of type 2 diabetes mellitus. It works by stimulating insulin secretion from pancreatic beta cells and improving insulin sensitivity. The drug is formulated as a tablet for once or twice-daily oral administration.
LOE Approaching
As an older agent with approaching loss of exclusivity and legacy portfolio status under R-Pharm US, the brand team is likely small and focused on maintenance rather than growth, limiting career expansion opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Tolazamide offers limited career growth in a mature, legacy portfolio asset with minimal job openings and declining market relevance. Positions available are primarily in maintenance-mode commercial and regulatory functions rather than strategic or innovative roles.
Brand ManagerField Sales
Worked on TOLAZAMIDE at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.